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A unique epitope on the gag protein of human immunodeficiency virus type 1 (HIV-1), located at amino acid
145 to 150, has been mapped by using a CD8+ cytotoxic T-lymphocyte (CTL) clone. This epitope is highly
conserved among 18 HIV-1 strains. The HIV-1 gag-specific human leukocyte antigen (HLA) class I-restricted
CD8+ CTL clone was generated from fresh peripheral blood mononuclear cells of an HIV-seropositive donor
by stimulation with y-irradiated allogeneic peripheral blood mononuclear cells in the presence of an anti-CD3
monoclonal antibody and recombinant interleukin-2. This gag-specific CTL clone killed autologous target cells
infected with a recombinant vaccinia virus containing the gag gene of HIV-1 and target cells pulsed with an
authentic p24&ag construct expressed in Escherichia coli. Fine specificity was determined by using a panel of
overlapping 30-amino-acid-long synthetic peptides and subsequently using smaller peptides to precisely map
the CTL domain on p24. The epitope is on a highly conserved region, and it overlaps with a major B-cell epitope
of gag. This CD8+ T-cell epitope is restricted by HLA-Cw3, which has not been previously identified as a
restricting element for human CTL responses.
The development of vaccines against AIDS has focused
primarily on the viral envelope gene product and has been
complicated by the emergence of neutralization escape mu-
tants (10, 12, 14) as well as sequence variation in the
envelope glycoprotein (40, 44). Previous candidate vaccines
that induced human immunodeficiency virus (HIV)-specific
neutralizing antibodies in chimpanzees did not protect these
animals from infection after challenge with live virus (14). A
recent report demonstrating protection of these animals
against homologous virus challenge for more than 6 months
after vaccination with recombinant glycoprotein gp120
leaves questions about the length of this protective immunity
(1). For a vaccine to be effective in humans, it should
provide protection for a long period after vaccination. It
should also elicit specific cytotoxic T-lymphocyte (CTL)
effectors that are able to eliminate cells which are infected by
virus that has escaped neutralization, either because of
antigenic drift or because of concentrations of antibody
inadequate to completely prevent infection. Efforts have
thus been focused on studying CTL responses against dif-
ferent HIV proteins; however, only a few epitopes recog-
nized by human CTL clones have been described.
A DR4-restricted gp120 epitope (amino acids [aa] 410 to
429) recognized by CD4+ clones has been identified, but this
region is not conserved in other HIV-1 strains (40). Several
* Corresponding author.
epitopes defined by reverse transcriptase-specific CTL
clones that were restricted by human leukocyte antigens
(HLA) A and B have been reported (50). Koenig et al. (16)
demonstrated an epitope of 10 amino acids (aa 73 to 82)
within nef recognized in association with HLA-A3 by a
CD8+ CTL clone. The only available information concern-
ing CTL epitopes on gag have been an HLA-B27-restricted
epitope on p24gag, analyzed by using bulk stimulated periph-
eral blood mononuclear cells (PBMC) as effector cells (26)
and HLA-A2-restricted epitopes that were described in bulk
cultures (5). In contrast to the envelope glycoprotein, there
is less heterogeneity exhibited by the internal viral proteins
of sequenced HIV-1 isolates, which makes characterization
of T-cell responses of these proteins a priority in view of
AIDS vaccine design. In this report, we describe the first
CTL response restricted by HLA-Cw3. This HLA antigen is
quite common, and this epitope on p24 is highly conserved
among HIV-1 strains.
MATERIALS AND METHODS
Recombinant vaccinia viruses and proteins. Vaccinia virus
(VAC) and three previously described recombinant vaccinia
viruses (VAC/gag, VACIpol, and VAC/gpl60) expressing
the gag (48), reverse transcriptase (50), and envelope (4)
genes of HIV-1 (IIIB strain), respectively, were used to
infect target cells for CTL assays.
Recombinant HIV-1 (IIIB strain) p24gag, expressed (6)
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and purified (13a) from Escherichia coli, was also used for
the preparation of target cells.
Preparation of synthetic peptides. Synthetic peptides of
HIV-1 p249ag were prepared and purified as described pre-
viously (11, 29) on the basis of the HIV-1 (III B strain)
sequence (34). The initial peptides tested overlapped with
adjacent peptides by 10 or 20 amino acids, and subsequently
shorter peptides were prepared and analyzed. The number-
ing of residues is based on the compilation of Myers et al.
(24).
Preparation of target cells. B-lymphoblastoid cell lines (B-
LCL) were established by Epstein-Barr virus transformation
of the PBMC from an HIV-1-infected donor (autologous) and
from major histocompatibility complex (MHC) HLA class I-
and II-matched or mismatched allogeneic donors. Culture
supernatant of B95-8 cells was used as an inoculum of
Epstein-Barr virus. These B95-8 cells were provided by T.
Sairenji of the University of Massachusetts Medical Center.
The B-LCL were either uninfected (control) or infected
with vaccinia viruses at a multiplicity of infection of 20 for 12
to 16 h, labeled with sodium [51Cr]chromate for 1.5 h,
washed thrice, and resuspended to give the appropriate
concentration for use as target cells in cytotoxicity assays.
The B-cell lines were also used as targets after overnight
pulsing with 100 pg of purified recombinant p24 protein per
ml or pulsing with synthetic peptides at a concentration of 20
to 100 ,ug/ml for 1 h. These B-cell lines were labeled with
51Cr, incubated for another hour, and then washed thrice
before use.
Preparation of effector cells. PBMC were obtained from the
blood of an asymptomatic HIV-1 antibody-positive individ-
ual (Walter Reed stage II) by Ficoll-Hypaque density gradi-
ent centrifugation. Cells were resuspended in RPMI 1640
medium supplemented with 10% fetal calf serum (GIBCO
Laboratories, Grand Island, N.Y.), penicillin (100 U/ml),
and streptomycin (100 U/ml) and used directly as effector
cells in cytotoxicity assays. To obtain T-cell clones, PBMC
were seeded at 50 cells per well in 96-well plates with 2 x 105
-y-irradiated normal PBMC from HIV-1-seronegative donors
in 0.2 ml of RPMI 1640 containing 10% fetal calf serum,
recombinant human interleukin-2 (100 U/ml; Cellular Prod-
ucts, Buffalo, N.Y.), and anti-CD3 antibody 12F6 (0.1 ,ug/ml)
as described by Walker et al. (49). Twice weekly, 0.1 ml of
medium was removed from each well and replaced with
fresh medium as described above. On day 14, when cell
proliferation was observed in all of the wells, cells were
transferred to 48-well flat-bottom plates (Costar) and further
cultured with 106 y-irradiated allogeneic feeders in 1 ml of
the same medium. These cell lines were restimulated every 2
weeks and subsequently used as effector cells in the assay
described below.
Cytotoxicity assays. Assays were performed in round-
bottom 96-well plates. Various concentrations of effector
cells in 0.1 ml of RPMI-10% fetal calf serum were added to
0.1 ml of a 51Cr-labeled target cell suspension (104 cells per
ml) in the wells to give the described effector/target (E/T)
ratios. After a 6-h incubation at 37°C, the supernatant was
harvested from each well and counted in a gamma counter.
The assays were performed in triplicate wells, and the
percent specific cell lysis was calculated by the formula 100
x (mean experimental release - mean spontaneous release)/
(mean total release - mean spontaneous release). The
results of an assay were excluded if the average spontaneous
release was .30% or if the viability prior to 51Cr labeling was
<80%.
HLA typing. Most of the donor lymphocytes used in these
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FIG. 1. Cytotoxic activity of fresh PBLs from an HIV-1-seropos-
itive subject, using four different E/T ratios. Autologous 51Cr-
labeled B-LCL were uninfected (control) or virus infected as indi-
cated. The K562 cell line was used as a control to monitor natural
killer cell activity.
experiments were typed for HLA-A, -B, -C, and -D antigens
on unfractionated PBMC by the Tissue Typing Laboratory
at the George Washington University Medical Center. Some
donor lymphocytes were tissue typed by using their Epstein-
Barr virus-transformed B-cell lines in the Tissue Typing
Laboratory at the University of Massachusetts Medical
Center.
Phenotypic analysis. Cell lines were stained with fluor-
escein isothiocyanate-conjugated monoclonal antibodies
(MAbs) anti-Leu4 (CD3), anti-Leu2 (CD8), anti-Leu3 (CD4),
and anti-Leulla (CD16), purchased from Becton Dickinson
and Co. (Mountain View, Calif.). The percentage of antigen-
positive cells was analyzed by fluorescence-activated cell
sorting (Becton Dickinson model 440 apparatus).
Antibody blocking of target cell lysis by CTL. MAbs B7/
21.7, S3/4, and OKIal recognize DP, DQ, and DR determi-
nants, respectively. MAb W6/32 recognizes a framework
determinant of HLA class I antigens. B7/21.7 and S3/4 were
kindly provided by Nancy Reinsmoen of the University of
Minnesota, Minneapolis. OKIal and W6/32 were provided
by John Sullivan of the University of Massachusetts Medical
Center. A total of 104 51Cr-labeled target cells in 0.1 ml were
incubated with 0.05 ml of 1:20 diluted MAbs for 30 min. The
effector cells were then added in 0.05 ml and incubated for 6
h. The percent specific cell lysis was determined as de-
scribed above.
RESULTS
HIV-1-specific cytotoxic activity in PBMC. Fresh PBMC
from an asymptomatic HIV-1-seropositive donor were
tested for specific lysis of autologous B-LCL that were
uninfected or infected with VAC, and the recombinant VAC/
gag and VAC/gpl60 as described in Materials and Methods.
The K562 cell line was used to monitor natural killer cell
activity (35). The results with different E/T ratios are pre-
sented in Fig. 1. No specific lytic activity of uninfected B-
LCL and little lytic activity on VAC-infected targets were
observed. Lysis of K562 cells was low. In contrast, we
detected significant HIV-1 gag-specific and envelope-spe-
cific killer cell activity. No specific cytotoxic activities were
detected with use of the PBMC of five HIV-1-seronegative
normal individuals (data not shown).
Establishment of HIV-1-specific CTL clones. One month
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FIG. 2. Specificity of clone 165 for HIV-1 p24 protein. CTL
clone 165 was tested for specific lysis of autologous B-LCL that
were uninfected (C) or expressing wild-type VAC, recombinant gag
(VAC/gag), or p24 protein. The K562 cell line was also used as
another target cell. The CTL assay was performed in triplicate at
E/T ratios of 10:1 (_) and 5:1 (M).
after initiation of the culture, the developing clones were
screened by testing for HIV-1-specific cytotoxic activity
with autologous B-LCL that were uninfected or infected
with VAC, VAC/gag, VACIpol, and VAC/gpl6O and with
the K562 cell line as a control. Two T-cell clones manifested
specificity for HIV-1 envelope (data not shown), and the
other clone (clone 165) was gag specific. There was no
cytotoxic activity specific for the pol gene product, reverse
transcriptase, and lysis of K562 cells was negligible. Pheno-
typic analysis showed that these cytotoxic clones were
CD3+ CD8+ CD4- Leull- (data not shown).
To further analyze antigenic specificity, we examined the
ability of the gag-specific CTL clone 165 to lyse target cells
pulsed with authentic HIV-1 p24gag protein purified from a
recombinant E. coli strain. We observed that clone 165
significantly lysed B-LCL target cells pulsed with purified
p24gag protein at levels comparable to the lysis of B-LCL
infected with VAC/gag, but they did not lyse uninfected or
VAC-infected targets (Fig. 2). We were unable to evaluate
the two env-specific CTL clones from this donor for HLA
restriction and epitope mapping because of their limited
ability to proliferate in vitro.
Characterization of an HIV-1 gag-specific CTL clone. (i)
Determination of the CTL epitope in p249ag. Fourteen over-
lapping synthetic peptides spanning the p24gag region were
used to map the viral epitope recognized by CTL clone 165.
As shown in Table 1, target cells pulsed with either synthetic
peptide 1 or 2 were significantly lysed, denoting that the
epitope recognized by this clone lies within the overlap
region.
The fine specificity of CTL clone 165 was further exam-
ined by using truncated peptides corresponding to the first
20-amino-acid sequence of peptide 1 (Table 2, experiment
A). Targets pulsed with peptides 90-17B and 90-17C lacking
the five or seven residues at the N-terminal end of peptide
90-17 were observed to have identical high levels of lysis,
whereas targets pulsed with peptides having carboxyl-termi-
nal deletions of four residues from peptide 90-17 were lysed
poorly (90-18, -18A, and -18B). Peptide 90-17A, which has
the first 13 amino acids of this region deleted, was not
recognized by the clone. Additional peptides containing
amino acid truncations from the N and C termini revealed
TABLE 1. Lysis of target cells pulsed with synthetic peptides of
HIV-1 p249ag by CD8+ CTL clone 165
Peptide
% Specific lysisa
No. Residues"
1 133-162 57.7
2 143-172 37.0
3 153-182 4.8
4-14 173-363 0
a Autologous B-LCL were pulsed with peptides at a final concentration of
50 ,ug/ml for 1 h before labeling with 5"Cr and used as targets for clone 165 in
a standard cytotoxicity assay. Percent specific lysis was determined at an E/T
ratio of 4:1.
I Residue numbering for the p248aR sequence is based on the HIV-1 (III B
strain) sequence.
that the epitope for this gag-specific CTL is located within aa
145 to 150 (Table 2, experiment B).
(ii) HLA restriction of cytolysis by CTL clone 165. We first
examined HLA restriction of the lysis of target cells infected
with VAC/gag by CTL clone 165, using MAbs to HLA
antigens. Anti-HLA class I MAb W6/32 inhibited the lysis of
VAC/gag-infected target cells by CTL clone 165, and this
inhibition was more apparent when a lower E/T ratio of 2.5:1
was used. The anti-class II MAbs to DP, DQ, and DR (B7/
21.7, S3/4, and OKIal, respectively) had no effect on the
lysis of the target cells by this gag-specific CD8+ T-cell
clone (Fig. 3). The results indicate that this CD8+ T-cell
clone lysed target cells in an HLA class I-restricted manner.
The gag-specific clone 165 was also tested for its lytic
activity on allogeneic B-LCL target cells infected with VAC/
gag matched at a specific HLA class I locus or unmatched,
as indicated in Fig. 4A. The HLA class I alleles of the donor
of clone 165 are A3,25, B18, Bw62, and Cw3. This CD8+
clone was able to lyse two allogeneic target cells that shared
Cw3 (Fig. 4A). Since target cells can also be sensitized to
virus-specific lysis in vitro by incubation with the appropri-
ate synthetic viral peptide (46), we examined the lysis of
other allogeneic targets that had been pulsed with peptide
90-17C, the core peptide which contained the epitope recog-
TABLE 2. Fine specificity of the epitope recognized
by CD8+ CTL clone 165
Peptide % Specific
Amino acid sequence lySiSa
No. Residuesb lss
Expt A
90-17 133-152 PIVQNIQGQMVHQAISPRTL 67.7
90-17A 146-152 AISPRTL -1.4
90-17B 138-152 IQGQMVHQAISPRTL 65.0
90-17C 140-152 GQMVHQAISPRTL 62.4
90-18 133-148 PIVQNIQGQMVHQAIS 9.6
90-18A 138-148 IQGQMVHQAIS 10.8
90-18B 140-148 GQMVHQAIS 3.1
Expt B
LD-1 140-152 GQMVHQAISPRTL 36.5
LD-3 145-151 QAISPRT 12.5
LD-4 145-150 QAISPR 25.2
90-17A 146-152 AISPRTL -1.8
a Autologous B-LCL were pulsed with peptides at a final concentration of
50 jg/ml for 1 h before labeling with 51Cr and used as targets for clone 165 in
a standard cytotoxicity assay. Percent specific lysis was determined at an E/T
ratio of 4:1.
bResidue numbering for the p249ag sequence is based on the HIV-1 (III B
strain) sequence.
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FIG. 3. Inhibition of HIV-1 gag-specific cytotoxicity by anti-
class I MAb W6/32. Target cells (104) were incubated with effector
cells at E/T ratios of 10:1 (=)-and 2.5:1 (M) for 6 h in the
presence of MAbs at a final dilution of 1:80. B7/21.7, S3/4, and
OKIal were used as anti-HLA DP, anti-HLA DQ, and anti-HLA
DR antibodies, respectively.
nized by this CTL clone. As shown in Fig. 4B, three of four
peptide-sensitized target cells that share Cw3 were lysed.
The failure to lyse one target cell that shared Cw3 may be
due to variability in HLA alleles, because the HLA deter-
minants which are recognized by the T-cell receptors differ
from those defined by typing sera. This has been shown to be
true for the HLA-A2 locus, where A2-restricted influenza A
virus-specific CTL clones lyse some allogenic target cells
Autologous
B18 Cw3
Cw3
A3
B18
B18
None
Autologous
Bw62 Cw3
Cw3
Cw3
Cw3
B18
Autologous
P815-Cw3 (H)
P815-Cw3 (M)
P815
A
0 20 40 60 80
B
I.
0 10 20 30
I0/ I Ly Is
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% Specific Lysis
FIG. 4. MHC restriction of clone 165. Autologous and allogeneic
targets matched at one or more HLA loci as indicated were infected
with VAC/gag (A) or pulsed for 1 h with peptide 90-17C (B).
HLA-Cw3-transfected P815 mouse mastocytoma cells and untrans-
fected P815 cells pulsed with peptide 90-17C were also used as target
cells (C). Percent specific lysis was determined at E/T ratios of 10:1
() and 3:1 (M).
sharing an A2 locus but not other targets bearing A2 variants
(2, 19). We were able to confirm the Cw3 restriction of clone
165 by using two transfected P815 (H-2d) mouse mastocy-
toma cells expressing human HLA-Cw3 that were pulsed
with peptide 90-17C in a CTL assay. As shown in Fig. 4C,
both cell lines expressing HLA-Cw3 were lysed by clone
165, while P815 control cells pulsed with the same peptide
were not lysed. These data clearly show that the epitope on
p249ag identified by clone 165 is definitely restricted by Cw3.
DISCUSSION
We described a CD8+ cytotoxic T-cell clone, 165, which
recognized an epitope that maps to a 6-amino-acid region (aa
145 to 150) of HIV-1 p249ag. This epitope is located within a
region of highly conserved amino acid sequence among
various HIV-1 isolates, with most strains (BH10, HXB2,
BH5, PV22, HAN, NDK, Z2, BRU, JH3, CDC4, ELI,
WMJ, SF2, RF, MN, MAL, and CDC-451) having complete
homology and only one isolate (OYI) having an alanine-to-
proline substitution at position 146 (24). Interestingly, this
HLA-Cw3-restricted CD8+ CTL epitope overlaps B-cell
epitopes of p249ag (aa 135 to 149 and 145 to 159) (23).
However, this site would not have been predicted by Ber-
zofsky's amphipathicity algorithm or by any of the widely
used computer models (7, 37, 43). This fact underlines the
importance of definitively identifying CTL epitopes by using
T-cell clones.
CTL responses to HIV-1 gag protein mediated by CD8-
positive HLA class I-restricted T cells have previously been
reported (5, 17, 26, 36, 48). In some studies they were
detected in variable degrees in fresh PBMC from HIV-1-
infected individuals without in vitro stimulation. Walker et
al. (48) reported low gag-specific CTL in three of eight HIV-
1-seropositive patients, while Riviere et al. (36) and Koup et
al. (17) found gag-specific CTL activity in over 80% of tested
HIV-1-seropositive subjects. In the study of Nixon et al.
(26), gag-specific CTL activity was detectable only after in
vitro mitogenic stimulation of the cells from HIV-infected
individuals.
Despite these bulk culture CTL responses, only a few
epitopes have been identified on HIV-1 gag. With use of
computer program-predicted gag epitopes, HLA-A2-re-
stricted epitopes were reported by Claverie et al. (5) in bulk
culture experiments using four sites within gag different
from that detected by clone 165, one of which was con-
served. Nixon et al. (26) used phytohemagglutinin-stimu-
lated PBMC of a seropositive donor that had been cultured
for 7 days and tested for lytic activity against target cells
pulsed with synthetic HIV-1 gag peptides. A CTL epitope
restricted by HLA-B27 was defined that comprises aa 265 to
279 and is highly conserved among HIV-1 isolates.
In contrast, sequence variation in the HIV-1 env protein
raises concerns associated with their potential use in subunit
vaccines based on env alone. For instance, an HLA-DR-
restricted gpl20-specific clone directed against an epitope
spanning residues 410 to 429 of gp120 demonstrated very
limited cross-reactivity against a range of HIV-1 variant
peptides (40). Thus, our results with the p24-specific T-cell
clone 165 and those of Nixon et al. (26) suggest that gag
sequences that contain highly conserved T-cell epitopes may
be very valuable and useful for inclusion in a combination
vaccine for HIV.
The isolation of an HIV-1 gag-specific CD8+ T-cell clone
from an HIV-1-seropositive and asymptomatic donor is
consistent with the gag-specific CTL activity that was ob-
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served in the freshly isolated PBMC. This indicates ongoing
antigenic stimulation in vivo since this cytotoxic activity was
detected directly in fresh blood and continued to be detected
in the cultured lymphocytes without in vitro HIV-1 antigenic
stimulation. This T-cell clone has demonstrated a persistent
gag-specific cytotoxic activity for the last 14 months and is
presumably not polyclonal since it recognizes a single small
peptide.
The highly conserved epitope on HIV-1 p24 is recognized
by the CD8+ clone 165 in an HLA-Cw3-restricted manner.
It has been assumed that HLA-C major histocompatible
antigens function similarly to the structurally related HLA-A
and -B antigens (13). This is the first report to our knowledge
that HLA-C antigens are restrictive elements for human
CTL, although it has been demonstrated recently that trans-
genic mice expressing the HLA-Cw3 gene developed CTL
responses to influenza and Sendai viruses which were Cw3
restricted (9). Cw3 is found in 20% of Caucasians and blacks,
62% of Native Americans, and 47% of Asians, and thus it is
a common HLA allele (45).
In general, CTLs can eliminate virus-infected cells, as has
been proven by the recovery from acute infections with
viruses such as influenza virus (20-22), lymphocytic chorio-
meningitis virus (3), cytomegalovirus (33, 35), varicella-
zoster virus (41, 42), and herpes simplex virus (25, 27) and in
persistent (lymphocytic choriomeningitis virus) infections
(28). Whether the role played by these CTLs is deleterious
(18, 32, 38, 39) or helpful to the HIV-infected host is unclear.
Their beneficial role is suggested by studies showing that the
level of CD8+ CTL detected in the blood of antibody-
positive HIV-1-infected individuals appears to decrease with
disease progression (30, 31), and this parallels the loss of
HIV-1-specific cytotoxicity (47). Others have shown that
CD8+ lymphocytes isolated from HIV-infected individuals
and simian immunodeficiency virus-infected macaques sup-
press HIV replication in vitro, although the mechanism of
antiviral activity remains to be defined (15, 51). It has also
been shown that synthetic viral lipopeptides can efficiently
prime animals for MHC class I-restricted CTL responses (8).
While the biologic relevance of human CTLs in HIV-1
infections is not certain, data in animal systems indicate that
they are likely to be important. Thus, there is a necessity to
collect a wide data base of highly conserved epitopes. If it is
shown that CTL responses to conserved epitopes provide
protection in primate models against disease, it may be
useful to combine several cross-reactive defined epitopes
that may induce protection in the majority of individuals
against HIV-1 disease.
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